Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Duliege

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Viral Immunology|March 25, 2000
Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulinM W Drulak, F J Malinoski, S A Fuller, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|October 1, 1995
Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complexA C Collier, R W Coombs, D Katzenstein, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 18, 1997
Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteersG Ferrari, W Humphrey, M J McElrath, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 7, 2001
Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected womenC K Cunningham, D W Wara, M Kang, et al.
International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement|January 1, 1992
CD4 immunoadhesins in anti-HIV therapy: new developmentsS M Chamow, A M Duliege, A Ammann, et al.
AIDS (London, England)|January 6, 1999
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation GroupR B Belshe, G J Gorse, M J Mulligan, et al.
The Journal of Infectious Diseases|March 18, 2000
Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 CollaboratorsW Borkowsky, D Wara, T Fenton, et al.
AIDS Research and Human Retroviruses|June 30, 2000
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation GroupM J McElrath, L Corey, D Montefiori, et al.
The Journal of Infectious Diseases|April 1, 1997
Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccinesS Zolla-Pazner, C Alving, R Belshe, et al.
The Journal of Infectious Diseases|July 9, 1999
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteersT G Evans, M C Keefer, K J Weinhold, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Viral Immunology|March 25, 2000
Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulinM W Drulak, F J Malinoski, S A Fuller, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|October 1, 1995
Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complexA C Collier, R W Coombs, D Katzenstein, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 18, 1997
Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteersG Ferrari, W Humphrey, M J McElrath, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 7, 2001
Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected womenC K Cunningham, D W Wara, M Kang, et al.
International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement|January 1, 1992
CD4 immunoadhesins in anti-HIV therapy: new developmentsS M Chamow, A M Duliege, A Ammann, et al.
AIDS (London, England)|January 6, 1999
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation GroupR B Belshe, G J Gorse, M J Mulligan, et al.
The Journal of Infectious Diseases|March 18, 2000
Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 CollaboratorsW Borkowsky, D Wara, T Fenton, et al.
AIDS Research and Human Retroviruses|June 30, 2000
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation GroupM J McElrath, L Corey, D Montefiori, et al.
The Journal of Infectious Diseases|April 1, 1997
Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccinesS Zolla-Pazner, C Alving, R Belshe, et al.
The Journal of Infectious Diseases|July 9, 1999
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteersT G Evans, M C Keefer, K J Weinhold, et al.
Pageof 3